Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — ...
Teva Pharmaceutical (TEVA) stock gains as the company succeeds in a mid-stage trial for its celiac disease therapy developed ...
Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s ...
GlobalData on MSN
Teva’s mAb shows benefit in celiac disease study
While Teva announced positive Phase II data, it has not yet confirmed Phase III plans.
Teva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of ...
Sept 2 () - Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday its experimental drug helped prevent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results